{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-117735","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.173097+00:00","generated_at":"2026-06-08T03:48:21.261143+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NRx Pharma Q3 net loss narrows to $6.1M; advances NRX-101 and ketamine plans","bullets":["Q3 net loss $6.1M vs $9.1M YoY; R&D expense $3.3M, G&A $2.5M; cash $8.9M.","Near completion of Phase 2b/3 NRX-101 trial for treatment-resistant bipolar depression; top-line data expected shortly after last patient visit.","Plan to submit NDA for IV ketamine (NRX-100) in Q1 2024; manufacturing partnership with Nephron signed.","Received term sheet for up to $30M anchor financing for a ketamine-focused spinoff entity.","Identified naked shorting disparities of ~1-1.5M shares; counsel instructed to demand closure of uncovered positions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-117735","json":"https://secwatch.observer/filing/0001104659-23-117735.json","markdown":"https://secwatch.observer/filing/0001104659-23-117735.md","text":"https://secwatch.observer/filing/0001104659-23-117735.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923117735/0001104659-23-117735-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923117735/tm2330650d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:48:21.261143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a022022c0508076a59c72be69675d139b74035ff","claim":"NRX Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, NRx Pharmaceuticals, Inc. issued a press release announcing its financial results for the third fiscal quarter ending September 30, 2023 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923117735/0001104659-23-117735-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}